Literature DB >> 18805009

E2F - at the crossroads of life and death.

Shirley Polager1, Doron Ginsberg.   

Abstract

The retinoblastoma tumor suppressor, pRb, restricts cell-cycle progression mainly by regulating members of the E2F-transcription-factor family. The Rb pathway is often inactivated in human tumors, resulting in deregulated-E2F activity that promotes proliferation or cell death, depending on the cellular context. Specifically, the outcome of deregulated-E2F activity is determined by integration of signals coming from the cellular DNA and the external environment. Alterations in cell proliferation and cell-death pathways are key features of transformed cells and, therefore, an understanding of the variables that determine the outcome of E2F activation is pivotal for cancer research and treatment. In this review, we discuss recent studies that have elucidated some of the signals affecting E2F activity and that have revealed additional E2F targets and functions, thereby enriching the understanding of this versatile transcription-factor family.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805009     DOI: 10.1016/j.tcb.2008.08.003

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  131 in total

Review 1.  Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death.

Authors:  Jaume Folch; Felix Junyent; Ester Verdaguer; Carme Auladell; Javier G Pizarro; Carlos Beas-Zarate; Mercè Pallàs; Antoni Camins
Journal:  Neurotox Res       Date:  2011-10-01       Impact factor: 3.911

2.  The ancient function of RB-E2F pathway: insights from its evolutionary history.

Authors:  Lihuan Cao; Bo Peng; Lei Yao; Xinming Zhang; Kuan Sun; Xianmei Yang; Long Yu
Journal:  Biol Direct       Date:  2010-09-20       Impact factor: 4.540

3.  Maternal gene expression profiling during pregnancy and preeclampsia in human peripheral blood mononuclear cells.

Authors:  A Rajakumar; T Chu; D E Handley; K D Bunce; B Burke; C A Hubel; A Jeyabalan; D G Peters
Journal:  Placenta       Date:  2010-11-13       Impact factor: 3.481

Review 4.  Regulation of senescence by microRNA biogenesis factors.

Authors:  Kotb Abdelmohsen; Subramanya Srikantan; Min-Ju Kang; Myriam Gorospe
Journal:  Ageing Res Rev       Date:  2012-01-28       Impact factor: 10.895

5.  Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.

Authors:  Matthew D Wilkerson; Xiaoying Yin; Katherine A Hoadley; Yufeng Liu; Michele C Hayward; Christopher R Cabanski; Kenneth Muldrew; C Ryan Miller; Scott H Randell; Mark A Socinski; Alden M Parsons; William K Funkhouser; Carrie B Lee; Patrick J Roberts; Leigh Thorne; Philip S Bernard; Charles M Perou; D Neil Hayes
Journal:  Clin Cancer Res       Date:  2010-07-19       Impact factor: 12.531

6.  MEF2D deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death in vitro.

Authors:  Nelsa L Estrella; Amanda L Clark; Cody A Desjardins; Sarah E Nocco; Francisco J Naya
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

Review 7.  Targeting CDK6 in cancer: State of the art and new insights.

Authors:  Solomon Tadesse; Mingfeng Yu; Malika Kumarasiri; Bich Thuy Le; Shudong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Functional variants at the miRNA binding sites of the E2F1 gene and its mRNA expression.

Authors:  Yunzhao Zhao; Lin Tang; Weiwei Nie; Zexing Wang; Xiaoxiang Guan
Journal:  Oncol Lett       Date:  2012-10-26       Impact factor: 2.967

Review 9.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

10.  pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737.

Authors:  J Bertin-Ciftci; B Barré; J Le Pen; L Maillet; C Couriaud; P Juin; F Braun
Journal:  Cell Death Differ       Date:  2013-02-22       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.